Skip to main content
. 2017 Mar 6;17:173. doi: 10.1186/s12885-017-3143-6

Fig. 1.

Fig. 1

Patient disposition at the time of data cut-off for primary safety analysis (August 2010) in the (a) selumetinib plus docetaxel and (b) selumetinib plus dacarbazine treatment arms. BID, twice daily; ppG-CSF, primary prophylactic granulocyte-colony stimulating factor